How many mitochondrial genomes does a cell have?

Hundreds to thousands, varying by tissue according to energy demand — not the two copies of a nuclear gene.

What is heteroplasmy?

A mixture of different mitochondrial DNA sequences within one cell, expressed as a proportion rather than present or absent.

Why do threshold effects occur?

Remaining normal genomes buffer a low proportion of a damaging variant. Above some proportion the buffering fails and dysfunction appears relatively abruptly.

MOTS-c (Mitochondrial Peptide)

Why Mitochondrial Genetics Is Not Like Nuclear Genetics

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Each cell contains many copies of the mitochondrial genome rather than the two copies of each nuclear gene. Copy number varies between tissues and individuals, and different copies can carry different sequences — a state called heteroplasmy.

Key facts

Nuclear genes: Two copies per cell
Mitochondrial genome: Many copies per cell
Heteroplasmy: Different copies, different sequences
Correlates with: Skeletal muscle oxidative capacity
Key study: Tian 2021, Aging Cell (PMID 34612579)
Measurement: P31 MR spectroscopy in that study

The structural difference

A nuclear gene comes in two copies, one per chromosome. Mitochondrial DNA does not work that way — each mitochondrion carries several genomes and each cell carries many mitochondria, so copy number runs to hundreds or thousands and varies by tissue according to energy demand.

What heteroplasmy means

That the many copies need not be identical. A mutation arising in one genome is not corrected against a partner copy the way a nuclear mutation can be, so a cell can carry a mixture of variant and wild-type sequences in some proportion. That proportion is the heteroplasmy load, and it is a continuous quantity rather than a present-or-absent state.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

Why that produces threshold effects

A low proportion of a damaging variant is buffered by the remaining normal genomes, so no consequence appears. Above some proportion the buffering fails and dysfunction emerges relatively abruptly. This threshold behaviour is characteristic of mitochondrial genetics and has no clean nuclear equivalent.

The functional correlation

Tian and colleagues reported in Aging Cell in 2021 that mitochondrial DNA copy number and heteroplasmy load correlate with skeletal muscle oxidative capacity, measured by phosphorus-31 magnetic resonance spectroscopy. That method assesses muscle energetics non-invasively in living participants, which is a considerably stronger design than inferring function from a tissue sample.

Why this frames the MOTS-c literature

MOTS-c is encoded in that genome and its reported effects concern skeletal muscle metabolism. Copy number and heteroplasmy both vary between people and both track muscle oxidative capacity, so the genomic context this peptide comes from is itself variable. That is relevant background to any measurement of circulating levels between individuals.

Where the measurement gets difficult

Soltész and colleagues examined mtDNA copy number changes, heteroplasmy and mutations across plasma-derived material and tissue in Molecular and Cellular Probes in 2022. Sampling matters: what is measured in circulation need not reflect what is present in a tissue, which is a general caution for any mitochondrial marker measured in blood.

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How many mitochondrial genomes does a cell have?: Hundreds to thousands, varying by tissue according to energy demand — not the two copies of a nuclear gene.
What is heteroplasmy?: A mixture of different mitochondrial DNA sequences within one cell, expressed as a proportion rather than present or absent.
Why do threshold effects occur?: Remaining normal genomes buffer a low proportion of a damaging variant. Above some proportion the buffering fails and dysfunction appears relatively abruptly.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum